Stock AnalizCorcept Therapeutics Inc. CORT
Biotechnology: Pharmaceutical Preparations · IPO 2004 · data as of November 13, 2026
Corcept Therapeutics Inc. (CORT) is a healthcare company listed in the US with a market value of about $8.0B. In the twelve months to September 30, 2026 it had revenue of $964M and net income of $159M, a net margin of 16.5%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (1/5).
Key numbers: a P/E of 57.4, a price to free cash flow of 41.0, 5-year revenue growth of 17% a year, a 5-year average ROIC of 18%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 68% above the current price.
Score: 2.8 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- Pays a dividend
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $964M | $761M | $675M | $482M | $402M | $366M | $354M | $306M | $251M | $159M | $81M |
| Net income | $159M | $100M | $141M | $106M | $101M | $113M | $106M | $94M | $75M | $129M | $8M |
| Free cash flow | $195M | $142M | $196M | $127M | $120M | $167M | $151M | $135M | $115M | $61M | $18M |
| EPS (diluted) | $1.27 | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 |
| Net margin | 16.5% | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% |
| ROIC | — | 5.4% | 17.4% | 18.0% | 19.6% | 29.8% | 19.6% | 24.1% | 26.6% | 21.9% | 18.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $142.60, 96% above the current price; targets range from $50.00 to $173.00; the consensus rating is “Buy”; expected EPS is $2.30 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Corcept Therapeutics’s P/E ratio?
About 57.4, based on the last twelve months of diluted earnings per share (forward P/E about 16.1).
Is Corcept Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 68% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Corcept Therapeutics pay a dividend?
Not currently.
Is Corcept Therapeutics a good stock to buy?
We do not give buy or sell advice. Corcept Therapeutics scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.